Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OKT3 + acyclovir
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
OKT3 + acyclovir is a combination therapy consisting of two distinct drugs:
- OKT3 (muromonab-CD3) is a murine monoclonal antibody that targets the CD3 receptor on human T lymphocytes. It is used as an immunosuppressive agent to prevent and treat acute organ transplant rejection by depleting or modulating T cells.
- Acyclovir is a synthetic nucleoside analog antiviral drug that inhibits viral DNA polymerase, thereby blocking replication of herpesviruses such as herpes simplex virus (HSV) and varicella-zoster virus (VZV).
The combination of OKT3 with prophylactic oral acyclovir has been studied in transplant recipients to reduce the risk of herpesvirus reactivation and infection during periods of intense immunosuppression induced by OKT3. Acyclovir may also help reduce the risk of posttransplantation lymphoproliferative disorder (PTLD) associated with high-dose immunosuppression.
- Other names
- muromonab-CD3 + acyclovir
02
Targets
Beyond the preview
Go deeper on OKT3 + acyclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OKT3 + acyclovir.